Your browser is no longer supported. Please, upgrade your browser.
PFE Pfizer Inc. monthly Stock Chart
PFE [NYSE]
Pfizer Inc.
IndexDJIA S&P500 P/E12.61 EPS (ttm)2.74 Insider Own0.04% Shs Outstand5.55B Perf Week7.71%
Market Cap187.42B Forward P/E11.15 EPS next Y3.09 Insider Trans-7.86% Shs Float5.55B Perf Month-4.17%
Income15.47B PEG- EPS next Q0.67 Inst Own73.00% Short Float0.97% Perf Quarter2.59%
Sales50.66B P/S3.70 EPS this Y62.30% Inst Trans-0.42% Short Ratio1.89 Perf Half Y-11.35%
Book/sh11.72 P/B2.94 EPS next Y7.54% ROA9.60% Target Price40.04 Perf Year-21.43%
Cash/sh1.91 P/C18.11 EPS next 5Y-0.20% ROE25.00% 52W Range27.88 - 44.56 Perf YTD-11.92%
Dividend1.52 P/FCF50.10 EPS past 5Y14.70% ROI14.70% 52W High-22.56% Beta0.67
Dividend %4.40% Quick Ratio0.80 Sales past 5Y0.90% Gross Margin80.40% 52W Low23.78% ATR0.91
Employees88300 Current Ratio1.00 Sales Q/Q-8.30% Oper. Margin32.10% RSI (14)50.77 Volatility2.01% 2.29%
OptionableYes Debt/Eq0.80 EPS Q/Q-10.30% Profit Margin31.20% Rel Volume0.91 Prev Close34.51
ShortableYes LT Debt/Eq0.56 EarningsJul 28 BMO Payout51.30% Avg Volume28.38M Price34.51
Recom2.50 SMA202.29% SMA50-4.11% SMA200-5.18% Volume25,730,066 Change0.00%
Jun-16-20Initiated SVB Leerink Mkt Perform $40
Feb-27-20Upgrade Standpoint Research Hold → Buy
Feb-27-20Initiated Barclays Equal Weight $36
Feb-06-20Initiated Mizuho Buy
Jan-07-20Initiated RBC Capital Mkts Outperform $46
Oct-17-19Resumed BofA/Merrill Neutral $37
Jul-30-19Downgrade Morgan Stanley Overweight → Equal-Weight $48 → $40
Jul-30-19Downgrade BofA/Merrill Buy → Neutral
Jun-04-19Resumed Morgan Stanley Overweight $48
Feb-20-19Resumed Citigroup Neutral $41
Jan-31-19Upgrade Credit Suisse Neutral → Outperform
Jan-31-19Upgrade Argus Hold → Buy
Jan-23-19Downgrade UBS Buy → Neutral
Dec-11-18Downgrade JP Morgan Overweight → Neutral
Nov-01-18Downgrade BMO Capital Markets Outperform → Market Perform
Jun-08-18Initiated Cantor Fitzgerald Overweight $45
Apr-05-18Downgrade Barclays Overweight → Equal Weight $41 → $38
Jan-29-18Reiterated SunTrust Hold $33 → $40
Sep-20-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-20-17Downgrade Credit Suisse Outperform → Neutral
Jul-06-20 05:26PM  
03:52PM  
02:42PM  
11:16AM  
07:00AM  
05:00AM  
Jul-05-20 02:58PM  
Jul-04-20 09:25AM  
Jul-03-20 09:01AM  
08:19AM  
Jul-02-20 10:03PM  
06:24PM  
05:35PM  
05:33PM  
05:01PM  
04:37PM  
04:16PM  
03:30PM  
03:14PM  
02:33PM  
02:10PM  
02:05PM  
01:48PM  
01:18PM  
01:12PM  
12:56PM  
12:43PM  
12:34PM  
12:01PM  
11:05AM  
11:00AM  
10:46AM  
10:14AM  
10:09AM  
09:59AM  
09:58AM  
09:45AM  
09:32AM  
09:09AM  
08:19AM  
08:10AM  
07:30AM  
07:19AM  
06:21AM  
05:09AM  
04:51AM  
03:32AM  
03:31AM  
03:04AM  
02:38AM  
12:06AM  
Jul-01-20 11:41PM  
11:07PM  
10:45PM  
10:40PM  
10:08PM  
08:44PM  
08:13PM  
07:28PM  
06:55PM  
06:07PM  
05:01PM  
04:59PM  
04:51PM  
04:34PM  
04:25PM  
04:09PM  
04:01PM  
03:56PM  
03:24PM  
03:18PM  
03:15PM  
02:51PM  
02:40PM  
02:36PM  
02:06PM  
01:50PM  
01:35PM  
01:35PM  
01:28PM  
01:05PM  
12:46PM  
12:28PM  
12:28PM  
12:07PM  
11:54AM  
11:54AM  
11:28AM  
11:06AM  
10:52AM  
10:52AM  
10:51AM  
10:45AM  
10:45AM  
10:33AM  
10:21AM  
10:18AM  
10:08AM  
10:04AM  
09:45AM  
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, such as cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; oncology, such as biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company and Astellas Pharma US, Inc.; licensing agreement with Akcea Therapeutics, Inc; strategic alliance with Verily Life Sciences LLC; collaboration agreements with Merck KGaA and Valneva SE; clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; material transfer and collaboration agreement with BioNTech SE to co-develop COVID-19 vaccine; clinical supply collaboration with Jiangsu Alphamab Biopharmaceuticals Co., Ltd; and research collaboration and license agreement with BioInvent International AB. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DAMICO JENNIFER B.SVP & ControllerJun 05Sale36.132,18178,8007,542Jun 08 04:29 PM
Dolsten MikaelPresident R&DMay 18Sale37.7895,3533,602,681174,918May 19 05:37 PM
DAMICO JENNIFER B.SVP & ControllerApr 29Sale38.352,18183,6419,647May 01 03:56 PM
JOHNSON RADY AExecutive Vice PresidentApr 29Sale38.3613,125503,47563,940May 01 03:56 PM
ROGERS DAWNExecutive Vice PresidentApr 29Sale38.1313,000495,6904,823May 01 03:56 PM
LANKLER DOUGLAS MExecutive Vice PresidentApr 29Sale37.8565,0002,460,37278,276May 01 03:56 PM
PFIZER INC10% OwnerMar 16Buy16.00312,5005,000,0001,481,719Mar 16 07:15 PM
GOETTLER MICHAELGroup PresidentFeb 28Option Exercise27.3722,852625,45953,036Mar 03 12:54 PM
JOHNSON RADY AExecutive Vice PresidentFeb 28Option Exercise27.3715,996437,81187,956Mar 03 12:54 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 28Option Exercise27.3738,8481,063,270172,542Mar 03 12:54 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentFeb 28Option Exercise27.3737,9341,038,254140,256Mar 03 12:54 PM
ROGERS DAWNExecutive Vice PresidentFeb 28Option Exercise27.3717,824487,84330,045Mar 03 12:54 PM
SUSMAN SALLYExecutive Vice PresidentFeb 28Option Exercise27.3791,4082,501,837222,496Mar 03 12:55 PM
YOUNG JOHN DGroup PresidentFeb 28Option Exercise27.37100,5482,751,999504,427Mar 03 12:55 PM
BOURLA ALBERTChairman & CEOFeb 28Option Exercise27.3733,135906,905232,888Mar 03 12:49 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 28Option Exercise27.3727,422750,540140,744Mar 03 12:49 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 28Option Exercise27.37173,6754,753,485556,084Mar 03 12:49 PM
YOUNG JOHN DGroup PresidentFeb 26Option Exercise34.59144,9285,013,060503,738Feb 28 07:32 PM
ROGERS DAWNExecutive Vice PresidentFeb 26Option Exercise34.5915,097522,20524,995Feb 28 07:28 PM
SUSMAN SALLYExecutive Vice PresidentFeb 26Option Exercise34.5972,4642,506,530180,558Feb 28 07:28 PM
JOHNSON RADY AExecutive Vice PresidentFeb 26Option Exercise34.5933,4141,155,79093,211Feb 28 07:24 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 26Option Exercise34.5988,5673,063,533189,936Feb 28 07:25 PM
GOETTLER MICHAELGroup PresidentFeb 26Option Exercise34.5920,129696,26245,557Feb 28 07:22 PM
Hwang AngelaGroup PresidentFeb 26Option Exercise34.5914,493501,31332,470Feb 28 07:22 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 26Option Exercise34.59144,9285,013,060482,320Feb 28 07:19 PM
BOURLA ALBERTChairman & CEOFeb 26Option Exercise34.5988,5673,063,533274,479Feb 28 07:16 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 26Option Exercise34.5924,155835,521131,196Feb 28 07:15 PM
Gottlieb ScottDirectorJan 30Buy37.001,00036,9974,000Jan 31 08:06 AM
PFIZER INC10% OwnerSep 17Buy18.0050,000900,0004,593,847Sep 19 04:19 PM
Gottlieb ScottDirectorAug 23Buy34.723,000104,1603,000Aug 26 09:27 AM